Wealth Enhancement Advisory Services’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.47M | Buy |
19,107
+13,301
| +229% | +$1.72M | ﹤0.01% | 1247 |
|
|
2025
Q1 | $642K | Sell |
5,806
-11,080
| -66% | -$1.23M | ﹤0.01% | 1858 |
|
|
2024
Q4 | $2.3M | Buy |
16,886
+11,240
| +199% | +$1.53M | ﹤0.01% | 1107 |
|
|
2024
Q3 | $651K | Sell |
5,646
-711
| -11% | -$81.9K | ﹤0.01% | 1629 |
|
|
2024
Q2 | $875K | Buy |
6,357
+1,613
| +34% | +$222K | ﹤0.01% | 1342 |
|
|
2024
Q1 | $654K | Buy |
4,744
+1,550
| +49% | +$214K | ﹤0.01% | 1439 |
|
|
2023
Q4 | $421K | Buy |
3,194
+316
| +11% | +$41.6K | ﹤0.01% | 1617 |
|
|
2023
Q3 | $324K | Buy |
+2,878
| New | +$324K | ﹤0.01% | 1691 |
|